Home Nav
Nextech Invest Logo

news

News

09.11.2018

Neon Therapeutics

Neon Therapeutics presents Updated Data at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

08.11.2018

Neon Therapeutics

Neon Therapeutics appoints Industry Veteran Robert Bazemore to its Board of Directors

08.11.2018

Kura Oncology

Kura Oncology adds Commercial Veteran Mary Szela to Board of Directors

01.11.2018

Kura Oncology

Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting

23.10.2018

IDEAYA Biosciences

IDEAYA Biosciences has entered into an exclusive license agreement with Novartis

22.10.2018

Kura Oncology

Kura Oncology presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC

16.10.2018

Revolution Medicines

Revolution Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets

09.10.2018

Revolution Medicines

Revolution Medicines announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors

06.10.2018

Blueprint Medicines

Blueprint Medicines announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers

03.10.2018

Neon Therapeutics

Neon Therapeutics presents Data from Ongoing Phase 1b NT-001 Clinical Trial at the European Society for Medical Oncology 2018 Congress

01.10.2018

Blueprint Medicines

Blueprint Medicines presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva

26.09.2018

Arvinas

Arvinas announces Pricing of Initial Public Offering

26.09.2018

Blueprint Medicines

Blueprint Medicines announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion

10.09.2018

TRACON Pharmaceuticals

TRACON Pharmaceuticals Announces Publication of Phase 1b Results for TRC105 in Combination with Inlyta® in Patients with Advanced or Metastatic RCC

29.08.2018

ImaginAb

ImaginAb and CPDC announce clinical trial supply manufacture and distribution agreement for ImaginAb’s CD8 immuno PET tracer

21.08.2018

Neon Therapeutics

Neon Therapeutics appoints Jolie M. Siegel as General Counsel

09.08.2018

Jounce Therapeutics

Jounce Therapeutics reports second quarter 2018 financial results

08.08.2018

Tracon Pharmaceuticals

Tracon Pharmaceuticals reports second quarter 2018 financial results and provides corporate update

06.08.2018

Kura Oncology

Kura Oncology reports second quarter 2018 financial results and provides corporate update

06.08.2018

Neon Therapeutics

Neon Therapeutics reports second quarter 2018 financial results and recent business highlights

Newsletter

Keep me updated about investment opportunities in the area of oncology and life sciences.

Register


Latest Newsletters

November 2018November 2018June 2018April 2018October 2017May 2017February 2017

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close

This website uses cookies to provide you with the best possible service. By using our website, you consent to the use of cookies in accordance with our privacy policy. Here you can find out more.